HUE032754T2 - CSF-1R inhibitorok agytumorok kezelésére - Google Patents

CSF-1R inhibitorok agytumorok kezelésére Download PDF

Info

Publication number
HUE032754T2
HUE032754T2 HUE12720761A HUE12720761A HUE032754T2 HU E032754 T2 HUE032754 T2 HU E032754T2 HU E12720761 A HUE12720761 A HU E12720761A HU E12720761 A HUE12720761 A HU E12720761A HU E032754 T2 HUE032754 T2 HU E032754T2
Authority
HU
Hungary
Prior art keywords
tumor
csf
blz945
compound
brain
Prior art date
Application number
HUE12720761A
Other languages
English (en)
Inventor
Dylan Daniel
Johanna Joyce
James Sutton
Original Assignee
Novartis Ag
Sloan-Kettering Inst For Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Sloan-Kettering Inst For Cancer Res filed Critical Novartis Ag
Publication of HUE032754T2 publication Critical patent/HUE032754T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (2)

  1. CSIM R. mik M^rok ag>earu>rok kead evere S^sl>sáaiml igiriyporäok
    kêplcti ^fpgytlP|, akol IV
    ebül IV Me vagy Égés R'5 vagy egy g\ ogyavsaúiag eökyjevfieM a éj a. esiilës alanyban. agytbmer kezelésében tëiténô alksiniaaäsie, V Vegyülni vagy gyögyä^eableg ellbgedhaté sije se I, igébygëël seerMtl alkslmseáem, aboi m (I.) képlete vegyülni
    X gvog>ás*;.ífc$g e; fogadható sója aa 1. Igénypont e^emm alkab^a^â$r%:àifô| (ü kcpíctií ^>8hd
  2. 4, V egt nie? N agy gux' S' ' aHug ·* &amp; godamo síp a oh' »' 'genvy^m^k ' xnru V »ko s'c »nt? ikkaimaoáam ahol a* agynaner egy gnema. 4 Yegyökt vagy gyógyásratdsg eïïogw$at&amp; #js' a 4 igÉWiMMefinù ;dkalma/.àvnv m-J. | gliön-n» glloklavteana nsuJtitefruc N \,v\ »! \λ'' -, wgN ! V W V Vu \ iV v"V ' ' 'V"' l\U" ^ X'V N>0? olkaltnaoesra, ahol a?' agytníror agy abdd aatrc»i>g»ma. (he leérne a giiohkstonnd), digedandroglkroie i.'pemlY»n»anak. vagy vaianeh Ogyee gkóma í. Vegyikí:! v agy gyégyáseaulag elfogadható sója a/ ekuo igátvpnmok bármely »ke v/eriam alkalnai/aata, ahal a vegüket eg> rgmkmv nn-apara vrohgàk» v/ermh hamm» alkakmuévre lunsulli 8 kegy oh.i vagy gy»kyas<fa»hae t’Nogaohaío vola a '! igény pom mmrmh alkalme/amte ahol m? gg^'nuey tg rágód a vamped veer antunga gen»'\g\ v,-e»\,k, N vom/an» 4» mmokwxnru! vagy antikok »? n \ek,oh*'n !"\ go ka»l t arraoie? d<< M g ghvp 'amgykotm :\kl»aí , ^ platina (ekvgpUnin),. alkha^b^ereíg például íem»v.»>k>núd uroomkmáo mhshdrok ígafltsnilí vagy etloűnlbj, I.'kuin. és cannahtnotdok kikäi váiavkvu
HUE12720761A 2011-05-05 2012-05-04 CSF-1R inhibitorok agytumorok kezelésére HUE032754T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161482723P 2011-05-05 2011-05-05
US201261624861P 2012-04-16 2012-04-16

Publications (1)

Publication Number Publication Date
HUE032754T2 true HUE032754T2 (hu) 2017-10-30

Family

ID=46062775

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12720761A HUE032754T2 (hu) 2011-05-05 2012-05-04 CSF-1R inhibitorok agytumorok kezelésére

Country Status (19)

Country Link
US (3) US20140065141A1 (hu)
EP (1) EP2704713B1 (hu)
JP (1) JP6046702B2 (hu)
KR (1) KR101938431B1 (hu)
CN (1) CN103501785B (hu)
BR (1) BR112013028095B1 (hu)
CA (1) CA2834696C (hu)
CY (1) CY1119642T1 (hu)
DK (1) DK2704713T3 (hu)
EA (1) EA023999B1 (hu)
ES (1) ES2622527T3 (hu)
HR (1) HRP20170593T1 (hu)
HU (1) HUE032754T2 (hu)
LT (1) LT2704713T (hu)
MX (1) MX347616B (hu)
PL (1) PL2704713T3 (hu)
PT (1) PT2704713T (hu)
SI (1) SI2704713T1 (hu)
WO (1) WO2012151523A1 (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014147631A1 (en) * 2013-03-22 2014-09-25 Natco Pharma Limited Formulation comprising gefitinib as oral suspension
US10722517B2 (en) 2015-05-08 2020-07-28 Memorial Sloan Kettering Cancer Center Compositions and methods for treatment of glioma
US10316097B2 (en) * 2015-05-27 2019-06-11 Ucb Biopharma Sprl Method for the treatment of epilepsy, epileptogenesis, seizures or convulsions by an anti-colony-stimulating factor 1 receptor (CSF-1R) antibody
CN108367070B (zh) * 2015-11-04 2022-10-28 杜克大学 免疫毒素与检查点抑制剂的组合治疗
WO2018069892A1 (en) * 2016-10-14 2018-04-19 Novartis Ag Crystalline forms of 4-(2-((1r,2r)-2-hydroxycyclohexylamino) benzothiazol-6-yloxy)-n-methylpicolinamide
US10537563B2 (en) 2016-10-14 2020-01-21 Novartis Ag Methods for treating ocular disease using inhibitors of CSF-1R
WO2018093591A1 (en) 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor
AU2018275894A1 (en) 2017-06-02 2019-12-12 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
AU2018275891A1 (en) 2017-06-02 2019-12-12 Juno Therapeutics, Inc. Articles of manufacture and methods related to toxicity associated with cell therapy
JP2020526194A (ja) 2017-06-29 2020-08-31 ジュノー セラピューティクス インコーポレイテッド 免疫療法薬と関連する毒性を評価するためのマウスモデル
MA50057A (fr) 2017-09-01 2020-07-08 Juno Therapeutics Inc Expression génique et évaluation d'un risque de développement d'une toxicité suite à une thérapie cellulaire
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
WO2020036987A1 (en) 2018-08-13 2020-02-20 Signablok, Inc. Peptides and compositions for targeted treatment and imaging
AU2019387497A1 (en) 2018-11-30 2021-06-24 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
KR20210110811A (ko) 2018-11-30 2021-09-09 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법에서 ｂ 세포 악성 종양의 투약 및 치료 방법
CN110468210A (zh) * 2019-09-12 2019-11-19 暨南大学 Cdc45作为胶质母细胞瘤标志物及其作为治疗靶点的应用
CN115398231A (zh) 2019-12-06 2022-11-25 朱诺治疗学股份有限公司 与治疗b细胞恶性肿瘤的细胞疗法相关的毒性和反应的相关方法
BR112023004719A2 (pt) * 2020-09-21 2023-04-18 Hutchison Medipharma Ltd Compostos heteroaromáticos e usos dos mesmos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100721656B1 (ko) 2005-11-01 2007-05-23 주식회사 엘지화학 유기 전기 소자
PL2010496T3 (pl) * 2006-04-14 2011-01-31 Astrazeneca Ab 4-Anilinochinolino-3-karboksyamidy jako inhibitory kinazy CSF-1R
CN101432281B (zh) * 2006-04-19 2013-08-28 诺瓦提斯公司 6-0-取代的苯并*唑和苯并噻唑化合物以及抑制csf-1r信号传导的方法
LT2010528T (lt) * 2006-04-19 2017-12-27 Novartis Ag 6-o-pakeistieji benzoksazolo junginiai bei csf-1r signalo perdavimo slopinimo būdai
UA93085C2 (en) 2006-04-20 2011-01-10 Янссен Фармацевтика Н.В. Inhibitors of c-fms kinase
AU2008254425A1 (en) * 2007-05-21 2008-11-27 Novartis Ag CSF-1R inhibitors, compositions, and methods of use

Also Published As

Publication number Publication date
AU2012250574A8 (en) 2016-07-28
AU2012250574A1 (en) 2013-11-28
EA023999B1 (ru) 2016-08-31
AU2012250574B2 (en) 2016-07-07
EP2704713A1 (en) 2014-03-12
CA2834696A1 (en) 2012-11-08
WO2012151523A1 (en) 2012-11-08
US20140065141A1 (en) 2014-03-06
CN103501785A (zh) 2014-01-08
EP2704713B1 (en) 2017-01-18
LT2704713T (lt) 2017-04-25
DK2704713T3 (en) 2017-04-24
US20150306085A1 (en) 2015-10-29
CA2834696C (en) 2019-07-23
PL2704713T3 (pl) 2017-08-31
KR20140029475A (ko) 2014-03-10
SI2704713T1 (sl) 2017-05-31
US10537561B2 (en) 2020-01-21
MX2013012939A (es) 2014-02-27
ES2622527T3 (es) 2017-07-06
US20190030013A1 (en) 2019-01-31
BR112013028095A2 (pt) 2016-12-27
BR112013028095B1 (pt) 2020-03-03
HRP20170593T1 (hr) 2017-07-14
JP2014513136A (ja) 2014-05-29
JP6046702B2 (ja) 2016-12-21
CN103501785B (zh) 2016-10-26
EA201391629A1 (ru) 2016-01-29
KR101938431B1 (ko) 2019-01-14
PT2704713T (pt) 2017-04-24
CY1119642T1 (el) 2018-04-04
MX347616B (es) 2017-05-04

Similar Documents

Publication Publication Date Title
DK2704713T3 (en) CSF-1R inhibitors for the treatment of brain tumors
KR102144452B1 (ko) 암 요법을 위한 병립 유전자 비활성화 생물표식과 표적들
EP3229831B1 (en) Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brain tumors
TWI814723B (zh) Kdm4抑制劑
BR112019017851A2 (pt) método para tratar câncer em um indivíduo que precisa do mesmo, método para identificar um indivíduo que tem um câncer como um candidato para o tratamento com um antagonista de smarca2, método para identificar uma célula cancerosa como sensível ao tratamento com um antagonista de smarca2, antagonista de smarca2 para uso no tratamento de câncer em um indivíduo que precisa do mesmo, antagonista de smarca2 para uso como um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo e uso do antagonista de smarca2 na fabricação de um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo
CN112512527A (zh) 恩扎妥林和btk抑制剂的组合及其用途
WO2019210109A1 (en) Abcb5 ligands and substrates
WO2019109074A1 (en) Mebendazole cancer therapies and methods of use
WO2012151541A1 (en) Csf-1r inhibitors for treatment of brain tumors
AU2012250574B8 (en) CSF-1R inhibitors for treatment of brain tumors
US20220347180A1 (en) Enhancing cancer therapy treatment with bh3 mimetics
BR112020000679A2 (pt) visando o complexo hdac2-sp3 para potencializar a função sináptica
US20230364087A1 (en) Therapeutic targeting of activated avil-induced sarcomas
EP3638690A1 (en) Methods to treat gliomas using a stat3 inhibitor
US10213449B2 (en) Compositions and methods for treating medulloblastoma
US20190282600A1 (en) Combination therapies targeting tert dependency for cancer therapy
US20210260057A1 (en) Compositions and methods targeting glutamine and its metabolism for diagnosing and treating cancer and therapy-associated side effects
CN114574580A (zh) 靶向a2br联合化疗在三阴性乳腺癌治疗中的应用
KR20240001703A (ko) 유비퀴틴 특이적 펩티다제 22 (usp22)의 억제제 및 질환 및 장애를 치료하기 위한 그의 용도
Rovin et al. Expression of HCMV IE1 in the U87MG Cell Line Augments Resistance to Temozolomide